- Report
- May 2024
- 133 Pages
Global
From €6138EUR$6,499USD£5,220GBP
- Report
- September 2024
- 343 Pages
Global
From €7508EUR$7,950USD£6,386GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
€1417EUR$1,500USD£1,205GBP
- Report
- March 2023
- 147 Pages
Global
From €4674EUR$4,949USD£3,975GBP
- Report
- January 2024
- 156 Pages
United States
€3589EUR$3,800USD£3,052GBP
- Report
- January 2024
- 114 Pages
United States
€3305EUR$3,500USD£2,811GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
Aclidinium is a long-acting muscarinic antagonist (LAMA) drug used to treat chronic obstructive pulmonary disease (COPD). It is administered via inhalation and works by relaxing the airways to improve breathing. Aclidinium is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It is one of several respiratory drugs used to treat COPD, along with bronchodilators, corticosteroids, and combination therapies.
Aclidinium is a popular choice for COPD treatment due to its long-acting effects and low risk of side effects. It is also used to prevent COPD exacerbations, which can be life-threatening. Aclidinium is available in both brand-name and generic forms.
Some companies in the Aclidinium market include AstraZeneca, which manufactures the brand-name drug, and several generic drug manufacturers such as Mylan, Teva Pharmaceuticals, and Sandoz. Show Less Read more